Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin Induction in DCD Kidney Transplants
NCT01239563Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Jan 2011
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin in kidney transplantation and ischemia-reperfusion injury (IRI) (2 arms), sponsored by University of Oxford. Primary endpoint: Delayed Graft Function at 7 days. Status: unknown.
02
Drugs
antithymocyte globulin
03
Conditions
kidney transplantationischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01239563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239563.